Methods
An email was sent to pharmacists and pharmacy technicians through the CF
Foundation LISTSERV and all responses regarding ELX/TEZ/IVA use in
children 6 to 11 years of age were collected. Data included patient
demographics (age, genetic mutations, weight, previous CFTR modulator
use and regimen), insurance type (state or commercial), prior
authorization attempts and overall approval or denial, and ELX/TEZ/IVA
regimen. Descriptive statistics were used to analyze data and a prior
authorization approval rate was calculated.